- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01847989
Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Volunteers
January 10, 2017 updated by: Novo Nordisk A/S
A Randomized, Placebo-controlled Single-dose, Double-blind Study of the Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Volunteers
This trial was conducted in Europe.
The aim of this trial was to investigate safety and pharmacokinetics of escalating single doses of catridecacog (recombinant factor XIII, rFXIII) in healthy volunteers.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Berkshire, United Kingdom, SL1 2 AD
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Normal platelet count and clotting parameters
- Adequate renal and hepatic function
- If female and of child-bearing potential, negative serum pregnancy test within 21 days of enrollment and a negative urine pregnancy test on admission to the clinical research unit
- If a sexually active male or a sexually active female of child-bearing potential,agreement to use a medically accepted form of contraception from the time of enrollment to completion of all follow-up study visits
- Negative drug and alcohol screens
Exclusion Criteria:
- Known antibodies or hypersensitivity to FXIII
- Known bleeding or hematologic disorder
- Known allergy to yeast
- Receipt of blood products within 30 days of screening
- Donation of blood within 30 days prior to enrollment
- Any surgical procedure in the 30 days prior to enrollment
- Previous history of autoimmune disorders involving autoantibodies, e.g., systemic lupus erythematosus
- Receipt of treatment with any experimental agent within 30 days of study enrollment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Single doses of placebo administered intravenously (IV) to two subjects in each of the five dose groups (2, 5, 10, 25 and 50 U/kg).
|
Experimental: rFXIII
|
Single doses of rFXIII administered intravenously (IV) to eight subjects in each of the five dose groups (2, 5, 10, 25 and 50 U/kg).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of adverse events
Time Frame: Days 0-28
|
Days 0-28
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of clinically significant changes from baseline in physical examination or laboratory measurements
Time Frame: Days 0-28
|
Days 0-28
|
Incidence of rFXIII antibodies, as measured by ELISA (Enzyme-Linked Immuno Sorbent Assay)
Time Frame: Days 0-28
|
Days 0-28
|
Incidence of yeast antibodies
Time Frame: Days 0-28
|
Days 0-28
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2003
Primary Completion (Actual)
May 1, 2003
Study Completion (Actual)
May 1, 2003
Study Registration Dates
First Submitted
May 2, 2013
First Submitted That Met QC Criteria
May 2, 2013
First Posted (Estimate)
May 7, 2013
Study Record Updates
Last Update Posted (Estimate)
January 11, 2017
Last Update Submitted That Met QC Criteria
January 10, 2017
Last Verified
January 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- F13-1661
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on catridecacog
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Congenital FXIII DeficiencyUnited States, Israel, United Kingdom
-
Novo Nordisk A/SCompletedAcquired Bleeding Disorder | Cardiac Surgery Requiring Cardiopulmonary BypassUnited States, Israel, Germany, Canada, Sweden, United Kingdom, Spain, Italy, Denmark, Japan
-
Novo Nordisk A/SCompletedAcquired Bleeding Disorder | Cardiac Surgery Requiring Cardiopulmonary BypassUnited States, Denmark, United Kingdom, Germany, Canada
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Congenital FXIII DeficiencyUnited States, Israel, Austria, Spain, Switzerland, Germany, Canada, France, United Kingdom, Italy, Finland
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Congenital FXIII DeficiencyUnited States
-
Novo Nordisk A/SCompletedHealthy | Congenital Bleeding Disorder | Congenital FXIII DeficiencyUnited Kingdom
-
Novo Nordisk A/SCompletedHealthy | Acquired Bleeding Disorder | Cardiac Surgery Requiring Cardiopulmonary BypassJapan
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Congenital FXIII DeficiencyFrance, United States, Israel, Spain, Switzerland, Germany, Canada, Japan, United Kingdom, Italy, Finland, Austria
-
Novo Nordisk A/SCompletedHealthy | Congenital Bleeding Disorder | Congenital FXIII DeficiencyUnited Kingdom
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Congenital FXIII DeficiencySpain, United States, Canada, Italy, United Kingdom, Hungary